lifted its annual profit forecast, banking on cost cuts, a smaller-than-feared drop in sales for its COVID antiviral treatment and strong demand for pneumonia vaccine, sending its shares up about 2% before the bell on Wednesday.
The drugmaker has responded with a $43 billion purchase of cancer drugmaker Seagen, a $4 billion cost-cut plan and internal restructuring. However, first-quarter sales from the vaccine came in at $354 million, missing analysts' average estimate of $496.5 million.Sales of Paxlovid stood at $2.04 billion for the quarter, beating analysts' expectations of $762.5 million.
Its market-leading pneumonia family of vaccines, sold under the brand name Prevnar, brought in sales of $1.69 billion, beating estimates of $1.66 billion.
Source: Financial Digest (financialdigest.net)
RULES:RESULTS RHPI:HEALTHCARE-PROVIDERS RHPI:PUBLIC-HEALTH MTPIX BACT BIODRG BIZ BLR CMPNY COVID GEN GENHLT HEA HECA HFAC HFAC1 HLTHSE HOT HPAS HUMDIS INFDIS MRCH MRCH1 NEWS1 PHAG08 PHAR PHAR08 PHAR1 PHMR PUBHEA PUBL PXP RES RESF RESPIR STX VACCIN AMERS US NAMER TOPNWS
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: wsfa12news - 🏆 338. / 59 Read more »
Source: screenrant - 🏆 7. / 94 Read more »
Source: CNBC - 🏆 12. / 72 Read more »
Source: nbcchicago - 🏆 545. / 51 Read more »
Source: NBCDFW - 🏆 288. / 63 Read more »
Source: screenrant - 🏆 7. / 94 Read more »